Vertex Pharmaceuticals news
The WiseView Research desk's stories that name Vertex Pharmaceuticals, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The VRTX page →
- HeadlineAhead of Vertex (VRTX) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
- HeadlineVertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
- HeadlineVertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
- HeadlineVertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript
- HeadlinePhase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026
- HeadlineVertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
- HeadlineVertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
- HeadlineVertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
- CongressRo Khanna bought $1,001 - $15,000 of VRTX
- HeadlineVertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
- HeadlineVertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
- CongressDavid Taylor sold $1,001 - $15,000 of VRTX
- CongressAlan Armstrong bought $1,001 - $15,000 of VRTX
- CongressRo Khanna bought $1,001 - $15,000 of VRTX
- CongressDavid Taylor sold $1,001 - $15,000 of VRTX
- CongressRo Khanna sold $1,001 - $15,000 of VRTX
- CongressRo Khanna bought $1,001 - $15,000 of VRTX
- CongressRo Khanna sold $1,001 - $15,000 of VRTX
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.